Table 1

General characteristics of randomized controlled trials
Overall, n (%) N=67
Funding source
governmental 12 (18)
private not for profit 3 (4)
private for profit 41 (61)
Private for profit plus other source 4 (6)
Not funded 3 (4)
Not reported 14 (21)
Publication language
English 67 (100)
Sample size
Median (Q1-Q3) 156 (74-355)
n <200 39 (58)
n ≥200 28 (42)
Type of cancer
Participants with different cancer types 47 (70)
Cancer type not reported 5 (7)
All participants with same cancer type 15 (22)
Lung 5 (33)
Colorectal 2 (13)
Gynecologic 2 (13)
Prostate 1 (7)
Breast 1 (7)
Pancreatic 1 (7)
Hematological 2 (13)
Hematological and solid tumors 1 (6)
Cancer as subgroup of the study 27 (40)
Intervention
LMWH 53 (79)
UFH 33 (49)
Vitamin K antagonist 20 (30)
Direct thrombin inhibitors 5 (7)
Fondaparinux 3 (4)
Comparator
Active treatment 47 (70)
Placebo 9 (13)
No treatment 11 (17)

LMWH=Low molecular weight heparin, UFH=Unfractioned Heparin, VTE=Venous thromboembolism, PE=Pulmonary embolism, DVT=Deep vein thrombosis.

Rada et al.

Rada et al. BMC Cancer 2013 13:76   doi:10.1186/1471-2407-13-76

Open Data